Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Rises By 206.2%

Posted by Brian Himes on Jul 15th, 2026

PicoCELA Inc. (NASDAQ:PCLA – Get Free Report) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 113,864 shares, a growth of 206.2% from the June 15th total of 37,187 shares. Based on an average trading volume of 822,239 shares, the days-to-cover ratio is currently 0.1 days. Approximately 284.7% of the shares of the stock are short sold.

Institutional Trading of PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. XTX Topco Ltd purchased a new stake in PicoCELA Inc. (NASDAQ:PCLA – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA at the end of the most recent reporting period.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

View Our Latest Research Report on PCLA

PicoCELA Stock Down 0.4%

Shares of PCLA traded down $0.02 during midday trading on Wednesday, reaching $4.48. 36,377 shares of the stock were exchanged, compared to its average volume of 792,846. The firm has a 50 day simple moving average of $4.99 and a 200-day simple moving average of $4.66. PicoCELA has a 12-month low of $1.35 and a 12-month high of $33.90.

PicoCELA Company Profile

(Get Free Report)

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.